Tag Archives: imfinzi

Immune Checkpoint Inhibitor May Change the Standard Treatment of Malignant Pleural Mesothelioma

Immune Checkpoint Inhibitor

The immune checkpoint inhibitor durvalumab could become a standard part of first-line mesothelioma treatment if the results of a new study hold true in a Phase 3 trial.  Australian researchers have become the latest to show the benefit of adding durvalumab to first-line chemotherapy for pleural mesothelioma. Chemotherapy is usually the first thing doctors use to treat pleural mesothelioma. But as many as half of mesothelioma patients do not respond to it. Researchers around the world are hopeful that adding an immune checkpoint inhibitor like durvalumab will lead to better response rates. What is an Immune Checkpoint Inhibitor? Mesothelioma cells survive and thrive in part because they have ways of protecting themselves. Chemotherapy drugs are less likely to hurt them … Continue reading Immune Checkpoint Inhibitor May Change the Standard Treatment of Malignant Pleural Mesothelioma »